NCT03981315

Brief Summary

Determine differences between lithogenic and non-lithogenic bile composition.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
62

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 4, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 10, 2019

Completed
4 months until next milestone

Study Start

First participant enrolled

October 1, 2019

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2021

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2022

Completed
Last Updated

June 10, 2019

Status Verified

June 1, 2019

Enrollment Period

2 years

First QC Date

June 4, 2019

Last Update Submit

June 7, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Differences of bile composition between cases and controls

    Bilirrubine in mg/dL

    Intra-operatively

Study Arms (3)

Lithogenic bile in symptomatic patient

Patients who are performed a cholecystectomy as a treatment of their gallbladder disease

Diagnostic Test: Bile testDiagnostic Test: Blood testDiagnostic Test: Gall stone studyDiagnostic Test: Microbiological bile test

Lithogenic bile in asymptomatic patient

Patients who are performed a cholecystectomy for another reason (cancer, organ donation) and gall stones are found

Diagnostic Test: Bile testDiagnostic Test: Blood testDiagnostic Test: Gall stone studyDiagnostic Test: Microbiological bile test

Non-lithogenic bile

Patients who are performed a cholecystectomy for another reason (cancer, organ donation) without gall stones

Diagnostic Test: Bile testDiagnostic Test: Blood testDiagnostic Test: Microbiological bile test

Interventions

Bile testDIAGNOSTIC_TEST

Analyze bile components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)

Lithogenic bile in asymptomatic patientLithogenic bile in symptomatic patientNon-lithogenic bile
Blood testDIAGNOSTIC_TEST

Analyze blood components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)

Lithogenic bile in asymptomatic patientLithogenic bile in symptomatic patientNon-lithogenic bile
Gall stone studyDIAGNOSTIC_TEST

Study of the extracted gall stones, analyzing their composition, type, etc.

Lithogenic bile in asymptomatic patientLithogenic bile in symptomatic patient

Determination of the microbiological composition of the bile

Lithogenic bile in asymptomatic patientLithogenic bile in symptomatic patientNon-lithogenic bile

Eligibility Criteria

Age16 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

It includes patients who suffer from gallstones, which are operated for that reason (open or laparoscopic cholecystectomy), and patients who go through the same intervention for other reasons (cancer, organ donation)

You may qualify if:

  • Patients included for an elective cholecystectomy.
  • Normal hepatic and renal function.
  • Able to understand the nature of the study.
  • Wish to participate in the study and sign the informed consent.
  • Patients included for an hepatectomy with gallbladder exeresis for surgery reasons, without lithiasis.
  • Patients included for peritoneal carcinomatosis surgery with gallbladder exeresis for surgery reasons, without lithiasis.
  • Organ donors.
  • Normal hepatic and renal function.
  • Able to understand the nature of the study.
  • Wish to participate in the study and sign the informed consent.

You may not qualify if:

  • Under 16 years old
  • Hepatic or renal insufficiency
  • Impossibility to understand the aim of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Universitario Son Espases

Palma de Mallorca, Mallorca, 07010, Spain

Location

Related Publications (7)

  • Gibney EJ. Asymptomatic gallstones. Br J Surg. 1990 Apr;77(4):368-72. doi: 10.1002/bjs.1800770405.

    PMID: 2187558BACKGROUND
  • Heller F, Bouchier IA. Cholesterol and bile salt studies on the bile of patients with cholesterol gallstones. Gut. 1973 Feb;14(2):83-8. doi: 10.1136/gut.14.2.83.

    PMID: 4696536BACKGROUND
  • Jayanthi V, Sarika S, Varghese J, Vaithiswaran V, Sharma M, Reddy MS, Srinivasan V, Reddy GM, Rela M, Kalkura S. Composition of gallbladder bile in healthy individuals and patients with gallstone disease from north and South India. Indian J Gastroenterol. 2016 Sep;35(5):347-353. doi: 10.1007/s12664-016-0685-5. Epub 2016 Sep 16.

    PMID: 27633032BACKGROUND
  • Mackay C, Crook JN, Smith DC, McAllister RA. The composition of hepatic and gallbladder bile in patients with gallstones. Gut. 1972 Oct;13(10):759-62. doi: 10.1136/gut.13.10.759.

    PMID: 5087065BACKGROUND
  • Reinhold JG, Ferguson LK, Hunsberger A. THE COMPOSITION OF HUMAN GALLBLADDER BILE AND ITS RELATIONSHIP TO CHOLELITHIASIS. J Clin Invest. 1937 May;16(3):367-82. doi: 10.1172/JCI100864. No abstract available.

    PMID: 16694485BACKGROUND
  • Shaffer EA. Gallstone disease: Epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol. 2006;20(6):981-96. doi: 10.1016/j.bpg.2006.05.004.

    PMID: 17127183BACKGROUND
  • Van Erpecum KJ. Pathogenesis of cholesterol and pigment gallstones: an update. Clin Res Hepatol Gastroenterol. 2011 Apr;35(4):281-7. doi: 10.1016/j.clinre.2011.01.009. Epub 2011 Feb 25.

    PMID: 21353662BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Bile and blood

MeSH Terms

Conditions

CholelithiasisGallstonesGallbladder Diseases

Interventions

Hematologic Tests

Condition Hierarchy (Ancestors)

Biliary Tract DiseasesDigestive System DiseasesCholecystolithiasisCalculiPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Clinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative Techniques

Central Study Contacts

Alejandro Gil Catalán

CONTACT

Francesc Xavier Molina Romero

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
2 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 4, 2019

First Posted

June 10, 2019

Study Start

October 1, 2019

Primary Completion

October 1, 2021

Study Completion

June 1, 2022

Last Updated

June 10, 2019

Record last verified: 2019-06

Data Sharing

IPD Sharing
Will not share

Locations